Immunotherapy with autologous dendritic cells (DCs) loaded with tumor lysate(s) from allogeneic tumor cell lines is a novel strategy to induce immune responses in cancer patients. We report on a pilot trial of autologous DCs pulsed with tumor cell lysate derived from allogeneic medullary thyroid carcinoma (MTC) cell lines in patients with metastatic MTC. The purpose of this study was to assess the safety, resulting immune responses and clinical activity of the DCs. DCs were injected into a groin lymph node at 3-week intervals. Monitoring included serial calcitonin tumor marker measurements, radiological imaging and immunological in vitro tests (T-cell Interferon-Á detection assay, T-cell cytotoxicity assay). Ten patients (median age 47 years, range 29-77) were enrolled. DC vaccinations were welltolerated and safe. After a median follow-up of 11 months, (range 7-26), 3 (30%) of 10 patients had stable disease, while 7 (70%) of the patients progressed during treatment. In 2 patients with stable disease, calcitonin decreased below treatment levels, paralleled by a T-cell-mediated immune response. Notably, treatment with DCs pulsed with a combination of different tumor cell lysates was followed by a calcitonin decrease in 4 patients who had previously experienced a calcitonin increase during monotherapy with DCs pulsed with a single lysate. Allogeneic tumor cell lysate-based DC immunotherapy is well-tolerated and safe. Combined treatment with different tumor cell lysate-pulsed DCs increases the likelihood of a calcitonin tumor marker response and should therefore be preferred over monotherapy with DCs pulsed with a single lysate.
Introduction
Medullary thyroid carcinoma (MTC) is a calcitonin-producing tumor of the parafollicular C cells which accounts for 5-10% of all thyroid malignancies (1) (2) (3) . MTC occurs sporadically, in a familial form, or associated with multiple endocrine neoplasia (MEN) type 2A or 2B. It has a slow but progressive clinical course with an early involvement of lymph nodes. Calcitonin is the most specific circulating marker and is widely used for diagnosis and monitoring. The solely curative treatment for MTC is total surgical removal of all neoplastic tissue which requires meticulous surgery. However, effective palliative treatments are lacking once distant metastases have occurred.
We have previously shown that tumor lysate-pulsed dendritic cells (DCs) are suited to stimulate antitumor T-cell responses against autologous MTC cells in vitro (4) . DCs can be generated in vitro from peripheral blood mononuclear cells (PBMCs) using GM-CSF and IL-4 (5). These immature DCs can be loaded with tumor lysate and matured by inflammatory stimuli including TNF·, IL-1ß or CD40-ligand (6, 7) . Because of their unique capacity to stimulate T-cells, DCs are a promising option for cancer immunotherapy, including surgically incurable MTC (8) (9) (10) (11) .
In two clinical trials using autologous tumor lysate-pulsed DCs we observed objective tumor marker responses and/ or disease stabilization in several patients with metastatic MTC (12, 13) . Encouraging results were also obtained by Schott et al who treated 7 patients and observed clinical and/or tumor marker responses in 3 patients, including a patient with a complete regression of detectable liver metastases and a significant reduction of pulmonary lesions (14) .
Immunotherapy with autologous DCs pulsed with tumor cell lysate derived from allogeneic tumor cell lines is a promising novel approach to induce antitumor immune responses in cancer patients (15) (16) (17) (18) (19) Table I . Eight (80%) of 10 patients had sporadic tumors and 2 (20%) patients had MEN-2 tumors. At initial diagnosis, 8 (80%) patients presented with a T4 tumor and 10 (100%) patients had positive lymph nodes. The mean interval between diagnosis and study entry was 74 months (range 1-220 months). All patients had calcitonin levels >500 pg/ml at the time of study entry. Five patients had previously received immunotherapy with autologous tumor lysate-pulsed DCs.
DC preparation. CD14 + cells were purified from PBMCs using a magnetic bead-conjugated anti-CD14 monoclonal antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). The cells were seeded at 1x10 6 /ml in RPMI-1640, supplemented with 1000 U/ml GM-CSF (Berlex Laboratories, Richmond, CA), 500 U/ml IL-4 (Strathmann PBH, Hamburg, Germany), 10% heat-inactivated fetal bovine serum (FBS, HyClone, Perbio, Logan, UT) and 50 μg/ml gentamycin (Gibco-BRL) in a 5% CO 2 humidified atmosphere at 37˚C. On day 5, DCs were pulsed with 200 μg/ml of tumor cell lysate for 12 h. They were then matured with 1 μg/ml TNF· (provided by H.R. Alexander Jr from the National Cancer Institute, MD) and 1000 U/ml IFN-Á (Boehringer Ingelheim, Vienna, Austria) for 12 h, followed by 50 ng/ml LPS for 4 h. Flow cytometric analysis of the DCs was performed before every vaccination and showed mature DCs positive for CD1a, CD40, CD80, CD 83 and CD86. For vaccine preparation, the cells were washed and dissolved in 300 μl phosphate-buffered saline (PBS, Gibco-BRL). DC vaccinations were administered 3-weekly on an outpatient basis. The cell suspension was injected into the patient's groin lymph node under ultrasound guidance. Table I . Patient characteristics. -
Tumor cells. MTC tumor cell lines (GSJO, KJOS-II, SHER-I)
were obtained from patients with MTC as previously described (21, 22) . GSJO cells were derived from the primary tumor of a patient with hereditary MTC. SHER-I and KJOS-II cells were obtained from 2 patients with sporadic MTC participating in this study: SHER-I tumor cells were derived from the primary tumor of patient 4, and KJOS-II tumor cells were derived from an axillary metastasis of patient 9. Tumor cells were cultured in DMEM F12 + 10% FBS and 50 μg/ml gentamycin. All cell lines tested negative for human pathogenic viruses.
Preparation of tumor cell lysate. Tumor cells (1-2x10 7 ) were washed in PBS, dissolved in sterile water and subjected to 5 freeze/thaw cycles. After centrifugation, the protein content was determined in the supernatant (Pierce Coomassie Plus Protein Assay, Rockford, IL) and aliquots were stored at -80˚C.
Clinical monitoring. Adverse events were graded according to the World Health Organization (WHO) toxicity criteria. All patients underwent assessment of tumor status at baseline and every 6 months thereafter using ultrasound, computed tomography scan, magnetic resonance imaging and/or PET scan. In all patients, calcitonin was measured at the beginning of the study and monthly thereafter. Clinical response was defined according to the WHO response criteria. Calcitonin tumor marker responses were defined as described previously (14) .
Autoantibodies (antinuclear, antihistone, anti-ds-DNA, anti-Ro/SSA, anti-La/SSB, anti-U1-RNA, anti-sm, anti-thyreoglobulin, anti-neutrophil cytoplasmic, anti-thyroid, antismooth muscle, anti-parietal cell, anti-mitochondrial, antiinsulin, anti-pancreatic islet and rheumatoid factors) were analyzed before and at least two times during the vaccination period.
In vitro cytotoxicity assays. T-cells obtained at different timepoints were cocultured with mature tumor lysate-pulsed DCs at a T:DC ratio of 5:1 in RPMI-1640 + 10% FBS without cytokines. On day 5, the T-cells were harvested and T-cellmediated cytotoxicity against MTC tumor cells was measured using a standard in vitro 4-h europium release assay as described previously (4) .
Intracytoplasmic interferon gamma (IFN-Á) detection assays.
Intracellular staining for IFN-Á expression by peripheral blood T-cells was performed as described previously (12, 13) . Briefly, 5x10 6 T-cells were cocultured with 1x10 6 mature tumor lysate-pulsed DCs for 18 h without addition of cytokines. Ten μmol/l Monensin (Sigma, Vienna, Austria) were added during the last 5 h to block protein secretion. After harvesting, the cells were washed and permeabilized using a commercially available kit (Immunotech, Marseille, France) and stained with a PE-labeled anti-IFN-Á and a FITC-labeled anti-CD3 antibody (Immunotech). Samples were analyzed on an EPICS XL flow cytometer (Beckman Coulter, Fullerton, CA).
Results
Treatment modalities. Treatment modalities are specified in Table II Clinical responses to treatment. DC vaccinations were well tolerated. No grade 3 or 4 toxicities or autoimmune reactions were observed. Table II shows the calcitonin tumor marker and radiological responses during the study. In patients 1 and 2, calcitonin decreased below pretreatment levels (-41 and -17%, respectively). In patient 3, calcitonin remained stable over 13 months (+3%). In the remaining patients, calcitonin Table II . Treatment modalities and clinical responses to treatment. -
increased, with a more than 2-fold calcitonin increase in patients 8-10. Correlating with the calcitonin changes during therapy, radiological imaging showed disease stabilization in patients 1, 2 and 3, including an objective regression of metastatic lesions in the liver and cervical lymph nodes in patient 1 which did not meet the criteria for a partial response. After a median follow-up of 11 months (range 7-26 months), 9 (90%) patients remain alive with disease whereas patient 9 died 20 months after study entry from rapidly progressive metastatic disease to the liver and lungs. Fig. 1 illustrates calcitonin levels, tumor lysates used for DC pulsing and periods of combined treatment with different tumor lysate-pulsed DCs. In the majority of patients, calcitonin levels increased during monotherapy with GSJOpulsed DCs, indicating poor immunological activity of DCs pulsed with this tumor lysate. We therefore introduced DCs pulsed with a second tumor lysate in patients 1-9, hypothesizing that a broader spectrum of tumor antigens for DC pulsing would increase the likelihood of an antitumor immune response. The second tumor lysate was derived from SHER-I tumor cells (patients 1-8) or KJOS-II tumor cells (patient 9). Table III lists the HLA type of patients and tumor cell lines. Noticeably, introduction of SHER-I-pulsed DCs was followed by a >70% calcitonin decrease (4190 pg/ml to 1160 pg/ml) in patient 1. Drops of calcitonin levels following introduction of SHER-I-pulsed DCs were also seen in patients 4 (calcitonin change: -25%), 5 (-20%) and 6 (-18%), all of whom had previously experienced increasing calcitonin levels during monotherapy with GSJO-pulsed DCs. In patient 2 where calcitonin had decreased moderately during monotherapy with GSJO-pulsed DCs, introduction of SHER-I-pulsed DCs was associated with a further calcitonin decrease. No effect of combined treatment with SHER-I-pulsed DCs was observed in patient 3 (no calcitonin change), as well as in patients 7 and 8 (calcitonin increase). Also, combined treatment with KJOS-II-pulsed DCs did not prevent the rapid increase of calcitonin levels in patient 9.
Efficacy of combined treatment with different tumor lysatepulsed DCs.

Cytotoxic T-cell responses.
To evaluate the immunostimulatory capacity of the DCs, we next assessed their ability to induce cytotoxic T-cell responses against the MTC tumor cells used for DC pulsing in vitro. For control, we tested T-cells stimulated with MTC tumor lysate-pulsed DCs against unrelated allogeneic PANC-1 pancreatic carcinoma cells. Fig. 2 illustrates the results of the T-cell cytotoxicity ONCOLOGY REPORTS 21: 1585 -1592 , 2009 1589 Table III . HLA type of patients and tumor cell lines.
- assays for patients 1 and 2 where calcitonin levels dropped below pretreatment levels, suggestive of an immunological response: in patient 1, SHER-I-pulsed DCs elicited a strong cytotoxic T-cell response against SHER-I tumor cells, correlating with the marked decline of calcitonin levels after SHER-I-pulsed DCs had been introduced. In contrast, no T-cell-mediated cytotoxicity against GSJO tumor cells was observed, reflecting the lack of clinical efficacy of GSJOpulsed DCs in this patient. In patient 2, cytotoxic T-cell responses against both GSJO and SHER-I tumor cells were observed, suggesting that immunoreactivity against tumor antigens from both tumor cell lines contributed to the decreasing calcitonin levels in this patient. In neither of the patients did MTC tumor lysate-pulsed DCs elicite a cytotoxic T-cell response against unrelated PANC-1 tumor cells.
----------------------------------------------------------------------------------------------------HLA type ----------------------------------------------------------------------------------------No. of patients A B C DR DQ -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
Intracytoplasmic IFN-Á detection assays.
To further characterize the immunological responses during treatment with MTC tumor lysate-pulsed DCs, serial intracytoplasmic IFN-Á detection assays were performed and correlated with calcitonin tumor marker levels. Fig. 3 illustrates the results of the intracytoplasmic IFN-Á detection assays performed in patient 1 where a decline of calcitonin tumor marker levels after introduction of SHER-I-pulsed DCs suggested an immunological response to DCs pulsed with this lysate; importantly, the decrease of calcitonin levels after 14 months of follow-up was paralleled by a 6.5-fold increase of SHER-Iimmunoreactive IFN-Á-positive T-cells between 14 and 17 months. Together with the data obtained in the T-cell cytotoxicity assays this further suggests that an antitumor T-cell response elicited by SHER-I-pulsed DCs contributed to the calcitonin tumor marker response in patient 1.
Discussion
We report the results of a pilot trial of autologous DCs pulsed with tumor lysate derived from allogeneic MTC tumor cells in patients with metastatic MTC. Treatment was well-tolerated and safe, and no autoimmune responses were observed. After a median follow-up of 11 months (range 7-26 months), 3 (30%) of 10 patients had stable disease, while 7 (70%) of the patients progressed during DC immunotherapy. Recently, it has been shown that autologous DCs loaded with allogeneic tumor cell lysate are a promising novel approach to induce antitumor T-cell responses in cancer patients (15) (16) (17) (18) (19) (20) . Loading DCs with allogeneic tumor cell lysate offers several advantages compared with autologous tumor lysate: first, no surgery is required to obtain tumor tissue for lysate preparation. Second, tumor cell lines are an unlimited source of tumor material since the cells can be easily passaged in vitro. Third, treatment is possible even for patients in whom autologous tumor material is no longer available, for patients whose metastatic lesions are not accessible to surgical removal, or for patients with unknown metastatic sites. Also, given an array of several tumor cell lines with different antigenic profiles, it is possible to deliver a broad spectrum of different tumor antigens to the DCs, thereby increasing the versatility of the DC vaccine to induce antitumor T-cell responses in individual patients.
In an ongoing collaborative effort we have established several MTC cell lines from various MTC tissue samples (21) (22) (23) (24) . The cell lines retain their neuroendocrine phenotype and display the biological features of neuroendocrine tumor cells at the molecular level. Considering the extremely small number of MTC cell lines currently available, these cells represent a unique tumor bank which can be used as a source of tumor antigens for DC immunotherapy in patients with MTC.
The primary aim of this trial was to assess the feasibility of allogeneic tumor lysate-based DC immunotherapy in patients with MTC. Treatment was well tolerated without side effects and could be performed on an outpatient basis. In none of the patients, evidence for the development of autoimmune disease was found.
The secondary aim was to assess the clinical efficacy of the DC vaccinations and to correlate the clinical responses to treatment with immunological assays in vitro. In our heavily metastasized patient cohort, stable disease was observed in three patients (patients 1-3). In two of these patients (patients 1 and 2), calcitonin decreased below pretreatment levels. For both patients, in vitro T-cell responses were observed: in patient 1, T-cell cytotoxicity assays showed a cytotoxic T-cell response against SHER-I tumor cells, and serial intracytoplasmic IFN-Á detection assays revealed that a sharp decline of calcitonin levels after introduction of SHER-Ipulsed DCs was paralleled by a 6.5-fold increase of SHER-Iimmunoreactive IFN-Á-positive T-cells. In patient 2, cytocorrelated with decreasing calcitonin levels during DC immunotherapy. In neither of the patients was a cytotoxic Tcell response against unrelated PANC-1 pancreatic cancer cells observed. This suggests that antitumor immune responses elicited by the DC vaccinations contributed to the calcitonin tumor marker decreases in responders to therapy.
We also compared combined treatment with different tumor lysate-pulsed DCs with the efficacy of single lysatebased DC therapy. Noticeably, calcitonin levels of patient 1 increased during monotherapy with GSJO-pulsed DCs but dropped by >70% after combination therapy with SHER-Ipulsed DCs was initiated. Decreases in calcitonin levels after onset of combined treatment with SHER-I-pulsed DCs were also observed in patients 4-6, all of whom had experienced rising calcitonin levels during monotherapy with GSJOpulsed DCs. This suggests that combining different tumor lysate-pulsed DCs into one vaccine increases the likelihood of inducing a calcitonin tumor marker response, conceivably due to delivery of a broader spectrum of tumor antigens to be recognized by patient T-cells.
Interestingly, an HLA match between patients and tumor cell lines was not required for inducing an antitumor T-cell response. This is in accordance with findings by Palucka et al who treated melanoma patients with DCs loaded with allogeneic melanoma cells and observed that CD8 + T-cell responses against an HLA-A0201 binding immunodominant MART-1 peptide could also be induced in HLA-A0201-negative patients. The authors were able to demonstrate that tumor-associated peptides may bind to several HLA molecules, enabling them to induce T-cell reactivity even in patients with a different HLA subtype (20) , a crucial prerequisite for immunotherapy with allogeneic tumor lysate-pulsed DCs.
Owing to a limited number of patients in our trial, conclusions regarding treatment efficacy of allogeneic tumor lysate-based DC immunotherapy in patients with MTC have to be drawn with caution. Disease stabilization together with calcitonin and immunological responses in selected patients are encouraging evidence for clinical and immunological activity of the DCs. However, the majority of patients progressed during treatment, calling for optimization of the DC vaccine to improve the overall efficacy of allogeneic tumor lysate-based DC immunotherapy. Identifying tumor cell combinations with increased immunogenicity for DC pulsing as well as introducing methods that enhance the intrinsic immunostimulatory capacity of the DCs [e.g. heat shock of the DCs (25) or replacing FBS by tumor lysate as protein supplementation during DC culture (26) ] are promising strategies in this regard, which we are currently testing in a follow-up clinical trial.
In conclusion, our study shows that immunotherapy with autologous DCs pulsed with allogeneic tumor cell lysate is a safe and well-tolerated novel treatment for patients with metastatic MTC. Combined treatment with different tumor lysate-pulsed DCs seems to enhance the likelihood of inducing an antitumor T-cell response and should therefore be preferred over treatment with DCs pulsed with a single lysate. A followup trial using combined treatment with different allogeneic tumor lysate-pulsed DCs that have been heat shocked for enhanced intrinsic immunogenicity is currently underway at our institution.
